Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

This test complements Fujirebio’s growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company’s leading position in advancing neuro biomarker research ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Dr. Soma Mandal, a board-certified internist at Summit Health in New Providence, New Jersey, says that getting a CBC test is "recommended for individuals of all ages as part of a routine health ...

To develop the test, researchers analyzed 6553 blood samples, 3076 from patients with cancer and 3477 from healthy individuals, divided into a training dataset of 4807 samples and an internal ...

A $500 annual blood testing membership promises to help consumers take their health into their own hands. Can it deliver?

The i-STAT TBI Blood Test will revolutionize the process and speed (15 minutes) at which traumatic brain injury (TBI) can be diagnosed.